IP Library Patent Application 17150385
Patent Application
App. No. 17/150,385

ORAL FORMULATIONS FOR MITIGATING ACUTE CANNABIS INTOXICATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/150,385
Abstract

Materials and method for mitigating the effects of acute cannabis intoxication are provided. For example, the present disclosure describes oral formulations comprising a peppercorn, a peppercorn substitute, or an extract thereof, a pharmaceutically acceptable excipient; and optionally CBD for use alleviating one or more unpleasant side effects of acute cannabis intoxication.

Claims (26)

1 . An oral formulation for mitigating an effect of acute cannabis intoxication comprising:

a peppercorn, a peppercorn substitute, or an extract thereof;

a pharmaceutically acceptable excipient; and

optionally CBD.

2 . The oral formulation of claim 1 , wherein the peppercorn is a black peppercorn.

3 . The oral formulation of claim 1 , comprising about 0.01 mg to 500 mg CBD.

4 . The oral formulation of claim 1 , further comprising a non-intoxicating cannabinoid.

5 . The oral formulation of claim 1 , comprising a quantity of peppercorn, peppercorn substitute or extract thereof to achieve a predetermined amount of terpenoid, optionally a predetermined amount of β-caryophyllene.

6 . The oral formulation of claim 1 , wherein the formulation is an oral spray.

7 . The oral formulation of claim 1 , wherein the formulation is a compressed tablet.

8 . The oral formulation of claim 1 , wherein the formulation is a candy-style lozenge.

9 . The oral formulation of claim 1 , further containing at least one sugar alcohol.

10 . The oral formulation of claim 1 , further comprising a hydrocolloid selected from the group consisting of gelatin, gum acacia, carob gum, carrageenan, ghatti gum, guar gum, karaya gum, pectin, tragacanth gum, locust bean gum, xanthan gum and combinations thereof.

11 . The oral formulation of claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of emulsifiers, surfactants, colorants, flavorants, taste modifiers, buffering agents, pH adjusting agents, stabilizers, sweeteners and combinations thereof.

12 . A method of mitigating an effect of acute cannabis intoxication in a subject in need thereof, the method comprising administering to the subject an oral formulation comprising:

a peppercorn, a peppercorn substitute, or an extract thereof;

a pharmaceutically acceptable excipient; and

optionally CBD.

13 . The method of claim 12 , wherein the peppercorn is a black peppercorn.

14 . The method of claim 12 , wherein the oral formulation comprises about 0.01 mg to 500 mg CBD.

15 . The method of claim 12 , wherein the oral formulation comprises a quantity of peppercorn, peppercorn substitute or extract thereof to achieve a predetermined amount of terpenoid, optionally a predetermined amount of pinene, piperine, or β-caryophyllene.

16 . The method of claim 12 , wherein the oral formulation is administered as an oral spray, a compressed tablet, or a candy-style lozenge.

17 . The method of claim 12 , wherein the oral formulation further comprises at least one sugar alcohol.

18 . The method of claim 12 , wherein the oral formulation further comprises a hydrocolloid selected from the group consisting of gelatin, gum acacia, carob gum, carrageenan, ghatti gum, guar gum, karaya gum, pectin, tragacanth gum, locust bean gum, xanthan gum and combinations thereof.

19 . The method of claim 12 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of emulsifiers, surfactants, colorants, flavorants, taste modifiers, buffering agents, pH adjusting agents, stabilizers, sweeteners and combinations thereof.

20 . The method of claim 12 , wherein the oral formulation is administered after the subject has used cannabis or administered concurrently with cannabis use.

Assignments (1)
SECURITY INTEREST Recorded Mar 25, 2021
From: VIREO HEALTH INTERNATIONAL, INC.
To: CHICAGO ATLANTIC ADMIN, LLC
Reel/Frame 055721/0544 →